RENCA macrobeads

BIOLOGICAL2 trials

Sponsors

The Rogosin Institute

Conditions

Colorectal Cancer MetastaticColorectal CancersPancreatic Adenocarcinoma MetastaticPancreatic Adenocarcinoma Non-resectable

Phase 2

Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer

CompletedNCT01053013

The Rogosin InstituteColorectal Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma Non-resectable

Start: 2010-04-15End: 2016-04-16Updated: 2021-05-12

Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared to Best Supportive Care in Colorectal Cancer Patients

CompletedNCT02046174

The Rogosin InstituteColorectal Cancers

Start: 2014-04-03End: 2018-10-22Updated: 2021-03-24

Related Papers

Abstract 1285: Regulation of docetaxel resistant cancer stem-like cells by RENCA macrobeads

Cancer Research2019-07-01

Abstract 1285: Regulation of docetaxel resistant cancer stem-like cells by RENCA macrobeads

Experimental and Molecular Therapeutics2019-07-01

Abstract 2731: Checkpoint inhibitor therapy in combination with the implantation of agarose encapsulated cancer cells inhibits tumor growth in a mouse model of osteosarcoma

Cancer Research2018-07-011 citations

Abstract 5552: Differential proteomic responses of luminal-A and basal-like breast cancer cell lines during growth inhibition induced by co-culture with agarose encapsulated murine renal adenocarcinoma (RENCA) cells

Cancer Research2017-07-01

18F-FDG PET/CT evaluation of tumor response to the implantation of RENCA macrobeads (RMB) in phase I and II clinical trials [INDBB 10091] in advanced, treatment-resistant metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2017-05-201 citations

Possible role of the systemic inflammatory reaction in defining tumor responder vs. nonresponder in cancer macrobead therapy.

Journal of Clinical Oncology2016-02-01